ReviewCancer prevention research (Philadelphia, Pa.)2012
Reducing HPV-associated cancer globally.
Review in Cancer prevention research (Philadelphia, Pa.), 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03604393 (Increasing Human Papillomavirus), which is not on this map. Cited by 122 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Increasing Human Papillomavirus (HPV) Immunization Rates: The Rural Adolescent Vaccine Enterprise (RAVE)
Who cites it
122 citing papers in PubMed, 236 citations in OpenAlex.
- Aurora kinase B as a therapeutic target in HPV-induced cervical cancer: mechanisms and future perspectives.Frontiers in oncology · 2026Review
- Adverse events following HPV vaccine reported to the Vaccine Adverse Event Reporting System.PloS one · 2026Article
- Virus-encoded circular RNAs in human cancer: mechanisms and clinical implications.Frontiers in cellular and infection microbiology · 2026Review
- Cost-effectiveness and epidemiological impact of gender-neutral vaccination against human papillomavirus in economically developed metropolises of Beijing, Shanghai, and Guangzhou, China.Human vaccines & immunotherapeutics · 2025Article
- Article
- Article
- The growing impact of human papilloma virus (HPV)-associated cancers in men in Costa Rica: epidemiological and economic burden.Frontiers in public health · 2025Article
- Nativity and racial/ethnic differences in HPV infection among U.S. adults, NHANES 2007-2016.Frontiers in public health · 2025Article
- VaxBot-HPV: A GPT-based Chatbot for Answering HPV Vaccine-related Questions.Research square · 2024Article
- Empowering standardization of cancer vaccines through ontology: enhanced modeling and data analysis.Journal of biomedical semantics · 2024Article
- A Novel Eight-Gene Signature for Lipid Metabolism Predicts the Progression of Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma.Reproductive sciences (Thousand Oaks, Calif.) · 2024Article
- A feasibility study assessing knowledge, vaccine hesitancy, and completion rates of free HPV vaccination in low-income uninsured adults.Preventive oncology & epidemiology · 2024Article
- Prevalence and Genotype Distribution of Human Papillomavirus Infection Among Women in Wuhan, China: A Retrospective Study.Infection and drug resistance · 2024Article
- Critical involvement of circular RNAs in virus-associated cancers.Genes & diseases · 2023Review
- Covid-19 and non-communicable diseases (NCDs) in Africa: a narrative review.African health sciences · 2023Review
- Health impact and cost-effectiveness of implementing gender-neutral vaccination with the 9-valent HPV vaccine in Hong Kong.Human vaccines & immunotherapeutics · 2023Article
- Functions of Circular RNA in Human Diseases and Illnesses.Non-coding RNA · 2023Review
- Human papillomavirus 16 E6 promotes angiogenesis of lung cancer via SNHG1.Cell biochemistry and biophysics · 2023Article
- Upper age limits for US male human papillomavirus vaccination for oropharyngeal cancer prevention: a microsimulation-based modeling study.Journal of the National Cancer Institute · 2023Article
- Modelling digital health data: The ExaMode ontology for computational pathology.Journal of pathology informatics · 2023Article
62 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Human papillomavirus (HPV)-related cancers are a major worldwide public health concern. Virtually all cervical cancer is HPV related, with 70% caused by HPV16 and -18. Variable proportions of certain noncervical cancers (e.g., anal, vulvar, and oropharyngeal) are HPV related; more than 90% of the HPV-related ones are caused by HPV16, -18. The HPV-related cancers are dominated by cervical cancer in the developing world, where cervical cancer screening is limited. In this setting, widespread uptake of current HPV vaccines by adolescent girls could reduce this cancer's incidence and mortality by approximately two-thirds, with cost-effective screening programs of adult women having the potential to reduce mortality more rapidly. In the industrialized world, some noncervical HPV-related cancers, especially oropharyngeal, are rapidly increasing, and now rival the incidence of cervical cancer, whose rates continue to decline thanks to established cervical screening programs. Therefore, reducing HPV-associated noncervical cancers with HPV vaccination has greater importance in the industrialized world, especially because there are no approved screening programs for these cancers. Preventing the substantial number of noncervical HPV cancers in men will require either "herd" immunity through high-vaccination rates in females or male vaccination. Current HPV vaccination can complement cervical screening in protecting against cervical cancer and may permit the safe reduction of screening intensity in industrialized countries. Second-generation HPV vaccines (active against a broader array of cervical cancer-related HPV types) could prevent an even higher proportion of cervical precancer and cancer and might permit further reductions in screening intensity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.